Dermatite atopica e prurigo nodularis

from Salute e Società · host Marco Caracciolo

Arriva anche in Italia nemolizumab, il primo farmaco biologico che agisce direttamente sul prurito cronico. AIFA ne ha approvato la rimborsabilità per la dermatite atopica moderata-grave e per la prurigo nodularis, due patologie che colpiscono complessivamente centinaia di migliaia di italiani.

Episode metadata supplied by the publisher feed · Published Jul 9, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

Dermatite atopica e prurigo nodularis

0:00 6:01

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Salute e Società?

This episode is 6 minutes long.

When was this Salute e Società episode published?

This episode was published on July 9, 2026.

Can I download this Salute e Società episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!